30 Years of 340B: Policymakers Must Act Now to Prioritize Transparency, Accountability, and Oversight
With the 340B program marking its 30th anniversary in November, we must ask: who is benefiting from this drug pricing […]
AIR340B to FTC: Outsized role of PBMs in safety-net program harms vulnerable patients
For vulnerable patients across America, getting the 340B Drug Pricing Program right could be the difference between receiving lifesaving care
340B Hospital Charity Care Levels Still Abysmal Despite Program Growth
With the unparalleled effects of the COVID-19 pandemic, it makes sense that health care is a top concern for Americans.
New Report Exposes Extreme Profit Retained from 340B Program by Covered Entities, Particularly for Oncology Medicines
Today, the Alliance for Integrity and Reform of 340B (AIR340B) released a new report by Health Capital Group that uncovered
Washington Needs to Put the Federal 340B Drug Discount Program Under the Microscope
Complex health care regulation is always a work in progress. Consider the Affordable Care Act (ACA), which has helped millions
Axios: This Safety-Net Program is Failing Many Vulnerable Patients
Many poor Americans, as well as those who lack good insurance, often struggle with the high costs of health care
New Poll: 86% of Voters Agree 340B Needs to Work Better for Patients
“The findings from this new poll are a stark reminder of the work we must do to save the 340B
AIR340B Stakeholder Forum 2021
On Wednesday, May 26, the Alliance for Integrity and Reform of 340B hosted its annual Stakeholder Summit to discuss the
Drug Channels: The 340B Program Soared to $38 Billion in 2020—Up 27% vs. 2019
Despite what you may have heard, the 340B Drug Pricing Program continues to thrive.
Biden Budget Offers Potential Oversight Tool on 340B Program
Citizens Against Government Waste (CAGW) has called for reforming the 340B program since 2014. The 340B safety net program was